RGNX sold off 12% today on news of a partial clinical hold on an NVS gene therapy trial using its vector.
After reading the press release I think this was an overreaction and the stock price will bounce back swiftly into RGNX earnings catalyst on 11/08/2019. It is sold off right to the bottom of its channel making for a beautiful setup!
This year has been full of positive catalysts for RGNX. As RGNX continues to build out their clinical pipeline, data catalyst from upcoming phase 2a report on their Wet-AMD gene therapy product could send the stock roaring higher. RGNX is set to report data Oct. 13, 2019 and the companies technical setup is quite nice. The Wet-AMD market is a lucrative opportunity...
RGNX and Novartis just received FDA approval of Gene Therapy treatment for Spinal Muscular Atrophy (SMA).
(SMA)Spinal Muscular Atrophy is a disease affecting the motor nerve cells in the spinal cord, taking away the ability to walk, eat, or breathe.
It is the number one genetic cause of death for infants.
According to a company filling, price tag for...
This stock has been following a channel up pattern and it seems very steady. I would buy at the intersection between the 14,48 fibonacci retracement level and the trendline i drew on the chart.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
RGNX
